Targeting the earliest signs of Alzheimer’s disease: The Zilkha Neurogenetic Institute

The Zilkha Neurogenetic Institute is pursuing new treatments for Alzheimer’s disease that could stop the disease process long before cognitive decline begins – treatments which would target early problems in the brain’s vascular system that may lead to dementia.

Learn more about our Alzheimer's research at the Keck School of Medicine of USC: keck.usc.edu/alzheimers